The correct answer is B. A review of case reports involving citalopram and QT prolongation or TdP pointed out the frequent presence of other significant risk and confounding factors, and the authors concluded that there is insufficient evidence to justify the warnings in place, especially given the absence of any reports of citalopram-induced sudden cardiac death among patients taking 60 mg daily and without other known risk factors.

Publication reference : Vieweg W.V., Hasnain M., Howland R.H., et. al.: Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?. Am J Med 2012; 125: pp. 859-868
Reference URL: https://pubmed.ncbi.nlm.nih.gov/22748401/